[vc_row][vc_column][vc_column_text]There’s never been a more exciting time for the field of cancer immunotherapy. New treatments are showing great promise and changing the way we think about cancer care.
At the forefront of this revolution is the idea of combining therapies to combat the many ways cancers can adapt and survive. As our understanding of cancer and the immune system grows, we are witnessing the emergence of a new vision – where practical combinations can benefit many more patients now faced with life-threatening disease.
Immune Checkpoint Inhibitors
The foundation of immuno-oncology
Checkpoint inhibitors work by releasing the brakes on specialized immune cells, allowing them to target and eliminate cancer. These drugs can be highly effective, as evidenced by Jimmy Carter’s recent high-profile response. Unfortunately, at this point only a minority of patients are likely to respond to these breakthrough drugs. That’s where the power of combination therapy can make a huge impact…
- Data suggest patients with a ‘T-cell rich’ profile are likely to respond.
- Immune-stimulating therapies (like OncoSec’s ImmunoPulse IL-12) have shown an ability to convert ‘T-cell poor’ tumors to ‘T-cell rich’ tumors by stimulating anti-cancer immune activity.
- Combining new therapies with checkpoint inhibitors may increase the number of patients that can benefit from these game-changing drugs.
The future of cancer care
The future of cancer careThe promise of combination therapy is forcing researchers and regulatory authorities to rethink how we approach cancer care. The era of single therapies competing for higher response rates is seemingly coming to an end. The focus is now shifting toward understanding how therapeutics work and evaluating how different approaches can work better together to improve outcomes for patients everywhere.[/vc_column_text][/vc_column][/vc_row]